Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px
Organisation › Details

Modus Therapeutics AB

Modus Therapeutics is a Swedish biotech company developing sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) and malaria. Sevuparin is currently being tested in a Phase II clinical study for SCD – a painful, inherited blood disorder affecting millions of people around the globe. SCD patients’ blood cells form a sickled shape, which makes blood flow to vital organs difficult, causing severe pain and even premature death. Sevuparin has the potential to improve the SCD patients’ blood flow reducing their pain and the amount of time they will need to spend in hospital. Modus plans to develop an administration form of sevuparin that the patient can self-administer allowing them to live a more normal life by preventing the painful episodes requiring hospital care. Modus is predominantly owned by KDev Investments AB, a part of Karolinska Development AB (Nasdaq Stockholm: KDEV) and Rosetta Capital. HealthCap now joins other large owners that include The Foundation for Baltic and European Studies (Östersjöstiftelsen), Ergomed and Praktikerinvest AB. *


Period Start 2016-10-20 renamed
Period End 2016-10-20 renamed
  Predecessor Dilaforette AB
Products Industry drug development
  Industry 2 sevuparin
Persons Person Donnelly, Ellen K. (Modus Therapeutics 201704– CEO before Pfizer)
  Person 2 Blom, Mats (Modus Therapeutics 201904– CFO before Zealand Pharma + Swedish Orphan International)
Region Region Stockholm
  Country Sweden
  Street 117 Sankt Eriksgatan
  City 113 43 Stockholm
  Tel +46-70-374-7156
    Address record changed: 2017-02-28
Basic data Employees n. a.
    * Document for �About Section�: Modus Therapeutics AB. (7/13/18). "Press Release: Modus Therapeutics Completes a SEK 140 Million Financing Led by HealthCap". Stockholm.
Record changed: 2019-07-13


Picture [iito] – Putting Information into Context 650x65px

More documents for Modus Therapeutics AB

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

» top